C Saba
Overview
Explore the profile of C Saba including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
165
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mason N, Selmic L, Ruple A, London C, Barber L, Weishaar K, et al.
Mol Ther
. 2025 Feb;
PMID: 39955616
A clinical trial in dogs with spontaneous osteosarcoma was performed to assess a recombinant Listeria expressing a chimeric human HER2/neu (ADXS31-164) as an adjunctive vaccine strategy to prevent metastatic disease...
2.
Soria J, DeBraud F, Bahleda R, Adamo B, Andre F, Dienstmann R, et al.
Ann Oncol
. 2020 Jun;
26(2):445.
PMID: 32590894
No abstract available.
3.
Craft S, Ekena J, Mayer B, Thamm D, Saba C, Chun R, et al.
Vet Comp Oncol
. 2017 Aug;
16(1):E61-E67.
PMID: 28840668
Glutathione S-transferase-theta (GSTT1) is a carcinogen detoxification enzyme, and low activity variants are associated with lymphoma in humans. We recently found a variant in the 3' untranslated region (UTR) of...
4.
Wilson-Robles H, Budke C, Miller T, Dervisis N, Novosad A, Wright Z, et al.
Vet Comp Oncol
. 2017 Apr;
15(4):1564-1571.
PMID: 28419683
Background: In humans geographical differences in the incidence and presentation of various cancers have been reported. However, much of this information has not been collected in veterinary oncology. Aim: The...
5.
Pierro J, Saba C, McLean K, Williams R, Karpuzoglu E, Prater R, et al.
Res Vet Sci
. 2017 Mar;
114:74-79.
PMID: 28319830
Metformin is an oral hypoglycemic drug that has been shown to inhibit cancer cell proliferation via up-regulation of AMPK (AMP-activated protein kinase), and possibly inhibition of mTOR (mammalian target of...
6.
Pierro J, Krick E, Flory A, Regan R, DeRegis C, Boudreaux B, et al.
Vet Comp Oncol
. 2016 Apr;
15(2):550-556.
PMID: 27094020
The purpose of this study was to describe the clinical presentation, potential causative agents, treatment and outcome of febrile neutropenia (FN) in chemotherapy-treated cats. Medical records from eight institutions were...
7.
Thiman J, Northrup N, Saba C, Clarke D, Regan R, Hamilton T, et al.
J Vet Pharmacol Ther
. 2016 Apr;
39(6):572-577.
PMID: 27086733
Use of compounded L-asparaginase became routine in veterinary oncology when manufacturing of Elspar was discontinued in 2012. The objective of this study was to evaluate the safety of compounded L-asparaginase...
8.
Soria J, DeBraud F, Bahleda R, Adamo B, Andre F, Dientsmann R, et al.
Ann Oncol
. 2014 Sep;
25(11):2244-2251.
PMID: 25193991
Background: Lucitanib is a potent, oral inhibitor fibroblast growth factor receptor types 1 and 2 (FGFR), vascular endothelial growth factor receptor types 1, 2, and 3 (VEGFR), platelet-derived growth factor...
9.
Turek M, Gogal Jr R, Saba C, Vandenplas M, Hill J, Feldhausser B, et al.
Res Vet Sci
. 2014 Mar;
96(2):304-7.
PMID: 24602916
Masitinib, a selective tyrosine kinase inhibitor, was investigated as a radiosensitizer in three primary feline injection-site sarcoma (ISS) cell lines. Sensitivity to masitinib was previously assessed via cell growth inhibition...
10.
Lawrence J, Karpuzoglu E, Vance A, Vandenplas M, Saba C, Turek M, et al.
Res Vet Sci
. 2013 Feb;
94(3):545-8.
PMID: 23375429
Feline injection site sarcoma (ISS) is a highly invasive soft tissue tumor that is commonly treated with radiation. Cellular deoxyribonucleic acid (DNA) is the principal target for the biologic effects...